Form D · Biotechnology

Ensoma, Inc.

Boston, MA · CIK 0001846902

Offering snapshot reported May 23, 2023 · SEC filing

Reported sold
$129M
Offering amount: $129M
Investors reported
22
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 23, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$64.5M$129MJan 9, 2023: $79,000,469.00Jan 9, 2023May 23, 2023: $129,000,467.00May 23, 2023

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$79,000,469 → $129,000,467
  • Reported investors19 → 22

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 23, 2023Amendment$129,000,467$49,999,998vs Jan 9, 202322SEC filing
Jan 9, 2023Initial$79,000,469No comparison19SEC filing
Feb 19, 2021Initial$40,549,910No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-470026

Source: Form D, filed May 23, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Chin Director
Kouki Harasaki Director
Stephen Knight Director
Emile Nuwaysir Director, Executive
Kush M Parmar Director
Albert Seymour Director
Nihal Sinha Director
Paula Soteropoulos Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
451 D Street, Suite 600
Boston, MA, 02210